US 11,077,145 B2Granted

Method for mass producing proteins in mesenchymal stem cells

AssigneeStemmedicare Co., Ltd.

InventorJang Ho Lee

Life of this patent

Estimating the term…

Loading patent…

Abstract

The present invention relates to the method for mass production of mesenchymal stem cell-derived proteins including various growth factors and cytokines, a mesenchymal stem cell conditioned medium containing a large amount of protein and produced by the above production method, cosmetic composition and pharmaceutical composition including the above conditioned medium for skin regeneration, anti-wrinkle, alopecia treatment, prevention of hair loss and promotion of hair growth. The method for mass production of the mesenchymal stem cell-derived protein of the present invention can greatly increase the amount of various growth factors and proteins which are known to be not expressed from mesenchymal stem cells or expressed only in very small amounts by the existing culture method, and the mesenchymal stem cell conditioned medium prepared by the above method contains a large amount of various kinds of cytokines and growth factors so that it has the excellent effect on skin regeneration, wrinkle improvement, prevention of hair loss, alopecia treatment and hair growth promotion.

Claims4

Dependent claims

A method for mass producing a mesenchymal stem cell-derived protein, the method comprising:

(A) storing mesenchymal stem cells in a cryopreservation medium solution at a temperature of −80° C.;
(B) inoculating the mesenchymal stem cells at a density of 20,000 cells/cm2;
(C) culturing the mesenchymal stem cells in a serum-free medium;
(D) obtaining a stem cell conditioned medium containing the protein produced by the mesenchymal stem cells after 120 hours of culture;
and
(E) extracting the mesenchymal stem cell-derived protein from the obtained stem cell conditioned medium,
wherein a total concentration of the extracted protein is 30 μg/ml to 70 μg/ml, and
wherein said protein is selected from the group consisting of AR, bFGF, BMP-5, BMP-7, GH, IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, SCF, TGF α, TGF β1, VEGF R3, VEGF-D, ICAM-1, IL-1a, IL-5, MIP-1a, MIP-b, MIP-d, RANTES, TNF R1, TNF RII, BDNF, BMP-4, b-NGF, EGF R, FGF-4, FGF-7, GDF-15, GDNF, HGF, IGFBP-6, IGF-I, Insulin, MCSF R, NGF R, NT-3, NT-4, OPG, PDGF-AA, PIGF, SCF R, VEGF, G-CSF, IL-2, IL-6, IL-8, IL-11, MCP-1, MCSF, MIG, TIMP-1, TIMP-2, TNFα, and TNFβ, or a combination thereof.

5 more elements

Dependencies are inferred from the claim text.

Facts

Application: 15/562,382Filed 1 Apr 2016
Priority: KR 10-2015-00477743 Apr 2015
Published: US 2018/0280441 A14 Oct 2018
Granted: 3 Aug 2021
Term ends: Not estimatedThe source records don’t support an estimate.

Classification20 codes

A61K 35/28
Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically…:…
A61K 9/0014
Galenical forms characterised by the site of application: skin, i.e. galenical aspects of topical compositions
A61K 38/39
From animals; from humans: connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
A61P 17/16
Drugs for dermatological disorders: emollients or protectives, e.g. against radiation

Family

US 2018/0280441 A1Pre-grant publication · published 4 Oct 2018
US 11,077,145 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key